GRTS vs. ATRA, BLUE, CLLS, REPL, TNYA, MGTX, SLDB, PSTX, ADAP, and BDTX
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Cellectis (CLLS), Replimune Group (REPL), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), and Black Diamond Therapeutics (BDTX). These companies are all part of the "biological products, except diagnostic" industry.
Gritstone bio (NASDAQ:GRTS) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
Atara Biotherapeutics received 288 more outperform votes than Gritstone bio when rated by MarketBeat users. However, 69.46% of users gave Gritstone bio an outperform vote while only 67.56% of users gave Atara Biotherapeutics an outperform vote.
In the previous week, Gritstone bio and Gritstone bio both had 3 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.97 beat Gritstone bio's score of 0.72 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.
Gritstone bio presently has a consensus price target of $4.75, suggesting a potential upside of 513.93%. Atara Biotherapeutics has a consensus price target of $28.00, suggesting a potential upside of 4,891.98%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Gritstone bio.
Gritstone bio has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
48.5% of Gritstone bio shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 4.6% of Gritstone bio shares are owned by company insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Atara Biotherapeutics has a net margin of -671.70% compared to Gritstone bio's net margin of -926.13%. Gritstone bio's return on equity of -232.42% beat Atara Biotherapeutics' return on equity.
Gritstone bio has higher revenue and earnings than Atara Biotherapeutics. Gritstone bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Gritstone bio beats Atara Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
